Patents by Inventor Peter Ordentlich

Peter Ordentlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Compounds and Methods of Using Them
    Publication number: 20100267779
    Abstract: Described herein are novel HDAC inhibitors, formulations containing them and methods of using them. In some embodiments, the HDAC inhibitors possess specific stereochemistry. In other embodiments, the compounds described herein are used in the treatment or prevention of histone deacetylase mediated disorders.
    Type: Application
    Filed: July 23, 2008
    Publication date: October 21, 2010
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: John F.W. Keana, Peter Ordentlich, Robert Goodenow
  • Administration of an Inhibitor of HDAC and an mTOR Inhibitor
    Publication number: 20090149511
    Abstract: Methods of treating patients with an HDAC inhibitor and an mTOR inhibitor are provided.
    Type: Application
    Filed: October 29, 2008
    Publication date: June 11, 2009
    Applicant: SYNDAX PHARMACEUTICALS, INC.
    Inventors: Konrad Burk, Peter Ordentlich, Robert Goodenow
  • COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20080242648
    Abstract: The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ER?+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
    Type: Application
    Filed: November 9, 2007
    Publication date: October 2, 2008
    Applicant: Syndax Pharmaceuticals, Inc., a California Corporation
    Inventors: Peter Ordentlich, Joanna Horobin, Martha Jo Whitehouse, Miranda Rees
  • SMRT co-repressors, transcriptional co-repressors that interact with nuclear hormone receptors
    Patent number: 7314747
    Abstract: The present invention relates to isolated polynucleotides encoding a family of silencing mediators of retinoic acid and thyroid hormone receptor (SMRT) isoforms, including vertebrate and invertebrate isoforms thereof. The invention also relates to polypeptide SMRT co-repressors encoded by invention SMRT polynucleotides, and to peptide portions thereof that can modulate transcriptional potential of a nuclear receptor. In addition, the invention relates to chimeric molecules and to complexes containing a SMRT co-repressor or peptide portion thereof, to antibodies that specifically bind such compositions, and to methods for identifying an agent that modulates the repressor potential of a SMRT co-repressor.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: January 1, 2008
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, J. Don Chen, Peter Ordentlich, Michael R. Downes
  • Substituted Pyrimidine Compositions and Methods of Use
    Publication number: 20070293464
    Abstract: Novel compositions and methods of using substituted pyrimidines which have the general formula: (I)
    Type: Application
    Filed: November 9, 2004
    Publication date: December 20, 2007
    Applicant: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Raju Mohan, Peter Ordentlich
  • Histone deacetylase, and uses therefor
    Patent number: 6673587
    Abstract: The present invention relates to the identification, isolation, sequencing and characterization of a new member of the histone deacetylase family, as well as its transcripts, gene products, associated sequence information, and related genes. The present invention also relates to methods for detecting and diagnosing carriers of normal and mutant alleles of these genes, methods for detecting and diagnosing diseases, methods of identifying genes and proteins related to or interacting with such genes and proteins, methods of screening for potential therapeutics for diseases, methods of treatment for diseases, and to cell lines and animal models useful in screening for and evaluating potentially useful therapies for diseases. In a particular aspect of the present invention, a novel family member, HDAC7, is described and its interaction with SMRT/N-CoR and mSin3A, its biochemical properties and subcellular localization are characterized.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: January 6, 2004
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Hung-Ying Kao, Michael Downes, Peter Ordentlich